can you take lyrica with depakote

A new study from UCLA researchers identified an animal model that could be used to study treatments for improving disabilities in multiple sclerosis patients.

Background

Multiple sclerosis (MS) is an autoimmune and neurodegenerative disease in which the immune system attacks nerves in the brain and spinal cord. There are numerous treatments aimed at immune mechanisms and reducing MS relapses, but none is designed to protect cells in the brain and spinal cord from damage. Existing treatments have limited effectiveness in slowing disability accumulation and none actually improve disabilities.

Identifying an animal model of disease progression is a critical step toward finding better treatments since the mechanisms underlying disease progression could be identified and then blocked.

Findings

Dr. Rhonda Voskuhl, MD, the Director of the UCLA Multiple Sclerosis Program, and Dr. Allan Mackenzie-Graham, PhD, an associate professor of neurology, have identified an animal model that shares many similarities with progressive MS.

Previously, acute and relapsing forms of experimental autoimmune encephalomyelitis (EAE), generic advair inhaler a mouse model characterized by inflammation within blood and spinal cord, played a central role in development of current anti-inflammatory treatments for MS. Here, Voskuhl and MacKenzie-Graham reported brain MRI and neuropathology analyses in a chronic form of EAE, revealing many features of neurodegeneration that are shared with MS. Beyond spinal cord, findings included effects on the cerebral cortex, cerebellum, and optic nerve, among others.

Impact

In the future, this model can be used by researchers to discover targets for treatments that improve walking, cognitive, coordination and visual disabilities in MS.

Journal

The study is published in the peer-reviewed journal Frontiers in Molecular Neuroscience as part of a series focused on the need for a model for progressive MS. See the study for the full list of funders. The authors declared no financial conflicts of interest.